CD8A and neoplasm: The IMMO-GLIO-01 glioma clinical trial published a case study of a 53-year old women with GBM in which longitudinal monitoring of her immune response during the treatment regimen, noted that a shift of the CD4:CD8 ratio was associated with magnetic resonance imaging (MRI) tumor progression [6].